TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia Leukemia (2016) 30, 959-962; doi:10.1038/leu. 2015.195 T-cell acute lymphoblastic leukemia (T-ALL) is a malignant disorder resulting from the leukemic transformation of T-cell precursors, and is one of the most common forms of cancer in children and is also found in adults. [1] [2] [3] The most frequent genetic abnormality in T-ALL is the dysregulation of transcription factor genes, including aberrant expression of TAL1/SCL. [1] [2] [3] TAL1 is ectopically expressed in 40-60% of T-ALL cases owing to chromosomal translocation, intrachromosomal rearrangement ('SIL-TAL deletion') or a somatic mutation in a non-coding intergenic element. 1, [3] [4] [5] We previously reported that TAL1 forms a positive interconnected autoregulatory loop with its regulatory partners GATA3, RUNX1 and MYB ('core regulatory circuits'). 3, 6 To identify critical downstream targets that contribute to T-cell leukemogenesis, we have also performed a loss-of-function RNA interference screen in the TAL1-positive T-ALL cell lines in our previous study. 6 Among the high-confidence TAL1 targets, only four genes, including the Tribbles homolog 2 (TRIB2), were selected by this screen. TRIB2 is a pseudo-kinase protein and has been implicated as an oncogene that contributes to acute myeloid leukemia (AML) by negatively regulating the C/EBPα tumor suppressor protein. 7, 8 TRIB2 is also a transcriptional target of the oncogene NOTCH1 in T-ALL. 9 However, the oncogenic role of TRIB2 in T-ALL pathogenesis, in particular, as a downstream consequence of the core regulatory circuits, has not been elucidated. In this study, we identified molecular pathways regulated by TRIB2 in T-ALL cells.
Western blot analysis showed that TRIB2 was expressed in all TAL1-positive T-ALL cell lines examined (Supplementary Figure 1a) . We performed microarray gene expression profiling after TRIB2 knockdown in Jurkat cells that expresses high levels of TAL1 and TRIB2 proteins. This analysis revealed that 123 and 77 gene probes were significantly down-and upregulated, respectively, after TRIB2 knockdown (Supplementary Figures 1b and c; Supplementary  Table 1) . A striking observation was the markedly decreased expression of the XIAP gene, which was found among the top 50 downregulated genes (Figure 1a , indicated by arrowheads), suggesting that TRIB2 positively regulates this gene. In fact, a significant positive correlation in messenger RNA (mRNA) expression between these two genes (P o0.05 by Pearson's r) was observed in primary T-ALL patient samples reported by Winter et al. 10 ( Supplementary Figure 1d) . XIAP is a member of the inhibitor of apoptosis family of proteins (IAP) and blocks apoptosis. 11 Western blot analysis showed that TRIB2 knockdown induced downregulation of the XIAP protein and cleavage of PARP and caspase-3 and -7 (markers of the intrinsic apoptosis pathway) in T-ALL cells (Figure 1b) . The similar result was observed with an independent small hairpin RNA (shRNA) targeting TRIB2 (Supplementary Figure 1e) . Other genes involved in the intrinsic pathway were not significantly altered after TRIB2 knockdown (Supplementary Table 2 ). Downregulation of the XIAP but not of other anti-apoptotic proteins, such as BCL2, BCLxL, MCL1 or c-IAP1, was observed in multiple T-ALL cell lines after TRIB2 knockdown (Figure 1c ) where cell growth was significantly inhibited (Supplementary Figure 1f) . Overexpression of XIAP or BCL2 was able to partially rescue the cells from apoptosis (Supplementary Figure 1g) and cell growth inhibition (Supplementary Figure 1h) after TRIB2 knockdown. These results suggest that T-ALL cells has been already 'primed' to cell death so that the cells undergo apoptosis when XIAP was downregulated. In contrast, the T-ALL cells overexpressing TRIB2 were more resistant to treatment with cytotoxic drugs (etoposide and doxorubicin) compared with the control cells transduced with an empty vector (Supplementary Figure 1i) . These results indicate that TRIB2 overexpression contributes to cell survival.
In addition to the apoptosis pathway, we found that genes regulated by TRIB2 included a number of genes directly regulated by the TAL1 complex that have been identified earlier by our chromatin immunoprecipitation sequencing and microarray analyses 6 (Supplementary Figure 2a) . Gene set enrichment analysis showed that many of the genes downregulated after knockdown of TAL1, GATA3 or RUNX1 were also significantly downregulated after TRIB2 knockdown (Figure 2a ). The result was validated by quantitative reverse transcription PCR analysis for representative TAL1 target genes (ALDH1A2 and LIG4; Supplementary Figure 2b) . These results indicate that TRIB2 selectively regulates expression of the direct targets of the TAL1 complex.
We next examined the mechanism of regulation of the TAL1 targets by TRIB2. Analysis of mRNA expression revealed that four major components of the TAL1 complex, namely TAL1, GATA3, RUNX1 and MYB, were downregulated after TRIB2 knockdown in Jurkat cells (Supplementary Figure 2b) . This trend was more significant at the protein level in the same cell line (Figure 2b , left), presumably owing to a high protein turnover of these factors. The similar result was observed with an independent shRNA targeting TRIB2 (Supplementary Figure 1e) . We previously reported that these genes positively regulate each other through an autoregulatory loop in this cell line. 4, 6 Indeed, overexpression of TRIB2 upregulated expression of all of these proteins in the same cell line both at the mRNA (Supplementary Figure 2c) and protein levels (Supplementary Figure 2d) . Notably, TAL1 was not downregulated after TRIB2 knockdown in two TAL1-positive cell lines (RPMI-8402 and CCRF-CEM; Figure 2b ) where TAL1 is driven by the SIL gene promoter, which is activated independently of the TAL1 complex. 12 In addition, downregulation of GATA3, RUNX1 and MYB was not significant in the TAL1-negative cell lines (Figure 2b ). Although additional study is needed to clarify the mechanism of regulation of the TAL1 complex by TRIB2, these results suggest that TRIB2 upregulates the expression of the TAL1 complex members by affecting the positive autoregulatory loop. Importantly, the decrease in protein expression of these transcription factors was also observed after TRIB2 knockdown in the XIAP-or BCL2-overexpressing cells (Supplementary Figures 2e and f) where apoptosis was blocked (Supplementary Figure 1g ; and see PARP cleavage in Supplementary Figures 2e and 2f) , demonstrating that the regulation of transcription factor proteins is not a result of cell death.
Interestingly, we found that expression of the E-protein E2A was upregulated by TRIB2 knockdown in Jurkat cells (Figure 2b ) and conversely was downregulated by TRIB2 overexpression (Supplementary Figure 2d) . The same trend was found in other TAL1-positive cell lines but not in the TAL1-negative cell lines Accepted article preview online 23 July 2015; advance online publication, 11 August 2015 Letters to the Editor (Figure 2b ). E2A is a heterodimerization partner of TAL1 but can also form a homodimer or heterodimer with other E-proteins (for example, HEB).
13 E2A has been reported as a tumor suppressor in T-ALL. 14 Our result indicates that E2A is negatively regulated by TRIB2 overexpression. The mRNA expression of E2A was not altered after knockdown or overexpression of TRIB2 (Supplementary Figures  2b and c) , indicating that E2A is regulated at the protein level. To further investigate this mechanism, we have treated the cells with the MG-132 proteasome inhibitor. The result demonstrated that MG-132 treatment increased protein expression of E2A, indicating that this protein is degraded in a proteasome-dependent manner (Supplementary Figure 2g) . MG-132 treatment was able to restore E2A expression close to the endogenous level after overexpression of TRIB2 protein without affecting the mRNA expression of E2A (Supplementary Figure 2g) . Our results indicate that TRIB2 affects the stability of E2A protein.
Finally, we analyzed the functional contribution of TRIB2 to the transcriptional regulation of the TAL1 targets in T-ALL. We have mapped by chromatin immunoprecipitation sequencing analysis the enhancer region for one of the high-confidence TAL1 targets, ALDH1A2, which is bound by TAL1 and its regulatory partners (HEB, E2A, LMO1, GATA3 and RUNX1; Supplementary Figure 2h) . 6, 15 We cloned this sequence into a luciferase reporter construct (Supplementary Figure 2i) . The introduction of the construct into a TAL1-positive T-ALL cell line (Jurkat) led to an increase in luciferase activity compared with a control transduced with an empty vector (Figure 2c; compare lanes 1 and 2) , indicating that the enhancer is activated by transcription factors endogenously expressed in T-ALL cells. Indeed, knockdown of the TAL1 complex members (TAL1, HEB, E2A, LMO1, GATA3 or RUNX1) inhibited the luciferase activity (Figure 2c; compare lanes 2-8) . Importantly, TRIB2 knockdown also significantly reduced the activity of this enhancer (Figure 2c ; compare lanes 2 and 9). We have also confirmed that DNA bindings of TAL1, GATA3 and RUNX1 proteins at this locus and the LIG4 gene were significantly reduced after TRIB2 knockdown (Supplementary Figure 2j) . These results indicate that TRIB2 coordinately and positively regulates expression of the TAL1 target genes. 210055_at_TSHR  212614_at_ARID5B  226183_at_GSK3B  231808_at_OIP5-AS1  224964_s_at_GNG2  224691_at_UHMK1  201972_at_ATP6V1A   226218_at_IL7R  209795_at_CD69  224416_s_at_MED28  205474_at_CRLF3  219696_at_DENND1B   226280_at_BNIP2  238787_at_DENND1B  202136_at_ZMYND11   241837_at_NA  212985_at_APBB2  225227_at_SKIL  224893_at_ATL3  205900_at_KRT1  226914_at_ARPC5L  228692_at_PREX2  41577_at_PPP1R16B   229934_at_NA  225858_s_at_XIAP  225859_at_XIAP  227930_at_AGO4  235309_at_RPS15A  201012_at_ANXA1  205798_at_IL7R  226725_at_SLFN5  200864_s_at_RAB11A  208892_s_at_DUSP6  215442_s_at_TSHR  203581_at_RAB4A  209267_s_at_SLC39A8   228992_at_MED28  215443_at_TSHR  201368_at_ZFP36L2  221973_at_LOC100506076   202647_s_at_NRAS  224959_at_SLC26A2 shGFP (2) shTRIB2 ( Taken together, our study shows that TRIB2 contributes to cell survival by regulating the XIAP anti-apoptotic gene in T-ALL cells. It is worth noting that XIAP is not a direct transcriptional target of TAL1, and that downregulation of the XIAP protein could be observed in T-ALL cell lines regardless of the TAL1 expression (Figure 1c ), indicating that TRIB2 may generally regulate XIAP expression independently of the TAL1 complex. According to the database by the Immunological Genome Project (http://www.immgen.org/), both Trib2 and Xiap genes are expressed in mouse T cells, suggesting that Trib2 may regulate Xiap expression in normal T cells. Detailed analysis with animal studies is needed to further elucidate the relationship between these two genes. Importantly, TRIB2 positively regulates the expression of TAL1, GATA3, RUNX1 and MYB and negatively regulates E2A. TRIB2 likely affects the stability of E2A protein. Notably, upregulation of E2A after TRIB2 knockdown was observed only in TAL1-positive cases. O'Neil et al.
14 have previously reported that haploinsufficiency of E2a was able to accelerate tumor onset and the penetrance of T-ALL in a transgenic murine model overexpressing Tal1, demonstrating the tumor suppressive function of E2A in TAL1-positive T-ALL. Our result suggests that TRIB2 overexpression reinforces the oncogenic transcriptional program in TAL1-positive T-ALL cells by altering the balance between the oncogenic TAL1 complex and the E2A tumor suppressor (Supplementary Figure 2k) . Our appreciation of the different molecular subtypes 1 and the complex genomic architecture of myeloma 2 has been recently enhanced by whole-exome and whole-genome DNA sequencing, indicating that myeloma cells typically harbor dozens of nonsynonymous mutations. 3, 4 Although myeloma is associated with recurrent mutations in a number of genes, including NRAS, KRAS, FAM46C, DIS3 and IRF4, 3 there is no evidence for hallmark 'unifying' mutations that have been found in other blood cancers, such as BRAF V600E in hairy cell leukemia 5 and MYD88 L265P in Waldenström macroglobulinemia. 6 The newly discovered myeloma alleles have raised the bar for preclinical mouse models of myeloma that can be used for interrogating pathways of tumor development and responses to new therapies. To rise to the challenge, more accurate, cost-effective and scalable models than what is currently available should be devised. In addition, next-generation mouse models of myeloma should be able to distinguish myeloma drivers from innocent bystander mutations, validate molecular targets for experimental myeloma interventions, elucidate mechanisms of acquired drug resistance and determine whether a myeloma gene operates in the tumor cells, the tumor microenvironment or both.
Encouraged by the push in the mouse cancer genetics community to supplement the time-consuming 'conventional' or 'germline' transgenic mouse models of cancer with more flexible and less expensive 'non-germline' models, 7 we have recently begun with the development of non-germline models for the in vivo validation of candidate myeloma genes. The cornerstone of the new method is adoptive B-cell transfer. Our first approach relied on Myc-transgenic cells. Although it provided proof-ofprinciple for the utility of adoptive B-cell transfer and showed that the tumor microenvironment is the critical source of interleukin (IL)-6 for neoplastic plasma cell (PC) development, 8 the requirement to prime the host mice with an intraperitoneal injection of pristane was a severe limitation. Treatment with pristane results in peritoneal plasmacytoma, an insufficient model for human myeloma. Here we demonstrate that this limitation can be overcome by employing a different type of B cell for the adoptive transfer: BCL2 + IL6
+ . This cell is prone to malignant transformation by virtue of classic oncogene collaboration; that is, a survivalenhancing BCL2 transgene 9 and a pro-inflammatory IL6 transgene.
10 BCL2 + IL6 + B cells can be readily isolated from secondary lymphoid tissues of double-transgenic mice (for example, spleen, mesenteric lymph node), genetically modified in vitro by viral gene transduction, and transferred to syngeneic BALB/c hosts primed with whole-body irradiation to facilitate the homeostatic expansion of the incoming B cells. The stable engraftment of these cells yields myeloma-like plasma cell neoplasms (PCNs) in immunocompetent hosts that have not been treated with intraperitoneal pristane (Figure 1a) .
To evaluate the potential of BCL2 + IL6 + B cells to give rise to myeloma-like tumors in genetically compatible hosts, B220 + CD45.2 + splenocytes were obtained from BCL2 + IL6 + mice and adoptively transferred, via retro-orbital IV injection, to CD45.1 + hosts pre-treated with a lethal dose of whole-body irradiation (Figure 1b, squares) . Tumor development was fully penetrant (100% tumor incidence) and tumor onset was short (61 days median, 50-80 days range) in all B-cell-reconstituted mice (n = 15). All tumors that arose from B cells that had been retrovirally transduced in vitro using a luciferase (Luc)-encoding cDNA gene exhibited strong reporter gene activity upon bioluminescence imaging in vivo (Figure 1c and Supplementary Figure 1) . Disappointingly, however, serum paraproteins were not detected (Supplementary Figure 2A) and the tumors were classified as diffuse large B-cell lymphoma (DLBCL) based on histopathologic criteria (Supplementary Figure 2B) .
To assess the possibility that the tumor pattern changes under conditions of less severe suppression of the host immune system, the tumor induction study was repeated using sub-lethally irradiated mice without bone marrow rescue (n = 12). Tumor onset was slowed (148 days median) and less predictable (64 days minimum, 353 days maximum) compared with lethally irradiated hosts, but tumor development was again complete (100% tumor incidence, Figure 1b, circles) . Importantly, histopathological investigations demonstrated that the majority of tumors (9 of 12, 75%) consisted of homogeneous sheets of abnormal Accepted article preview online 23 July 2015; advance online publication, 11 August 2015
